Acetylcysteine

Generic Name
Acetylcysteine
Brand Names
Acetadote
Drug Type
Small Molecule
Chemical Formula
C5H9NO3S
CAS Number
616-91-1
Unique Ingredient Identifier
WYQ7N0BPYC
Background

Acetylcysteine is an antioxidant and glutathione inducer indicated for mucolytic therapy and the treatment of acetaminophen overdose. Acetylcysteine has also been studied for a wide variety of off-label indications with mixed results.

Acetylcysteine was granted FDA approval on 14 September 1963.

Indication

Acetylcysteine is indicated for mucolytic therapy and in the management of acetaminophen overdose.

Associated Conditions
Acetaminophen Overdose, Chronic Rhinitis, Corneal Diseases, Corneal ulceration, Crusting Rhinitis, Keratopathy, Rhinitis, Sinusitis, Vasomotor Rhinitis, Acute Rhinitis, Subacute Rhinitis
Associated Therapies
Airway secretion clearance therapy
Clinical Trials
Related News

Effect of Acetylcysteine in Pediatric Acute Pyelonephritis.

First Posted Date
2014-03-06
Last Posted Date
2016-04-20
Lead Sponsor
Shahid Beheshti University of Medical Sciences
Target Recruit Count
70
Registration Number
NCT02080182
Locations
🇮🇷

Pediatric Infections Research Center, Tehran, Iran, Islamic Republic of

Acute Renal Failure Post Liver Transplantation

Not Applicable
Completed
Conditions
Acute Renal Failure
Interventions
Drug: N-acetylcysteine
Drug: Placebo
First Posted Date
2013-07-24
Last Posted Date
2020-02-21
Lead Sponsor
Baylor Research Institute
Target Recruit Count
30
Registration Number
NCT01907061
Locations
🇺🇸

Annette C. and Harold C. Simmons Tranplant Institute at Baylor Medical Center Dallas, Dallas, Texas, United States

Clomiphene Plus N-acetyl Cysteine for Induction of Ovulation in Newly Diagnosed Pcos.

Phase 4
Completed
Conditions
PCOS
Interventions
Drug: NAC
First Posted Date
2013-07-11
Last Posted Date
2020-08-12
Lead Sponsor
Woman's Health University Hospital, Egypt
Target Recruit Count
200
Registration Number
NCT01896492

Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy

First Posted Date
2013-07-03
Last Posted Date
2013-07-03
Lead Sponsor
The University of The West Indies
Target Recruit Count
30
Registration Number
NCT01891292
Locations
🇯🇲

Sickle Cell Unit, Kingston, Jamaica

Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention

Phase 3
Active, not recruiting
Conditions
Acute ST Segment Elevation Myocardial Infarction
Interventions
Drug: Saline
Drug: NAC
First Posted Date
2013-06-14
Last Posted Date
2024-04-09
Lead Sponsor
Suleyman Demirel University
Target Recruit Count
100
Registration Number
NCT01878344
Locations
🇹🇷

Suleyman Demirel University, Isparta, Mediterranean Region, Turkey

Effectiveness of N-acetylcysteine on Preservation Solution During Liver Transplantation

First Posted Date
2013-05-31
Last Posted Date
2018-08-13
Lead Sponsor
Instituto de Investigacion Sanitaria La Fe
Target Recruit Count
214
Registration Number
NCT01866644
Locations
🇪🇸

Hospital Universitari i Politècnic La Fe, Valencia, Spain

N-Acetylcysteine in Patients With Sickle Cell Disease

Phase 3
Completed
Conditions
Sickle Cell Disease
Interventions
Drug: Placebo
Drug: N-Acetylcysteine
First Posted Date
2013-05-08
Last Posted Date
2016-07-04
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Target Recruit Count
96
Registration Number
NCT01849016
Locations
🇬🇧

Guys' & St. Thomas Hospital, London, United Kingdom

🇳🇱

Erasmus Medical Center, Rotterdam, Netherlands

🇧🇪

CHU St. Pierre, Brussels, Belgium

and more 8 locations

The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain

Phase 2
Completed
Conditions
Neuropathic Pain
Interventions
Drug: N-acetyl-l-cysteine
First Posted Date
2013-04-25
Last Posted Date
2018-05-14
Lead Sponsor
Virginia Commonwealth University
Target Recruit Count
11
Registration Number
NCT01840345
Locations
🇺🇸

Virginia Commonwealth University, Richmond, Virginia, United States

A Pilot Study of N-acetylcysteine in Thrombotic Thrombocytopenia Purpura

Early Phase 1
Completed
Conditions
Purpura, Thrombotic Thrombocytopenic
TTP
Interventions
Drug: N-Acetylcysteine
First Posted Date
2013-03-11
Last Posted Date
2017-09-20
Lead Sponsor
Bloodworks
Target Recruit Count
3
Registration Number
NCT01808521
Locations
🇺🇸

Puget Sound Blood Center, Seattle, Washington, United States

A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease

First Posted Date
2013-02-27
Last Posted Date
2020-07-09
Lead Sponsor
Bloodworks
Target Recruit Count
21
Registration Number
NCT01800526
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy